In order to determine (f age is a f ac to r in heal ing aft er tympanic membrane grafting. the author compa red the result s of 163 co nsecutive type I tympanoplasties pe rformed on pati ent s aged 20 to 40 with those of 97 consecutive type I tympanopl asties p erform ed on pati ents age d 65 and olde r. The tympanoplasties were perform ed ove r a 5-year peri od. The postop erative[o llowup per iod range dfrom6 to lO years. The authorfound no dif f erence in the success or fa ilure of the graft-tak e rates between the two gro ups . The refo re. it wo uld app ear that in ge neral, age is not a fa ctor in the success orfailure ofheal ing fo llow ing tympan oplasty surgery.
Introduction
Adva nces in medi cin e have co nsiderably imp roved the life ex pectancy and the quality of life itself of individuals age d 65 and olde r. Bec ause of this, the dem ographics of our society as a whole has shifte d, as the geriatric age gro up now makes up a larger segment of the total population tha n eve r before. As a res ult of thi s trend, there is a grea ter demand for medical and surg ical care by old er ind ividu als.
One area that has been greatly affec ted by these shifting population and healt h tren ds is the treatmen t of hearing imp airm ent s. In the pas t, there was ge neral resignation to the fact that "Grampa can 't hear. " Toda y, this situation is no longer accept ed by "Grampa" or his fami ly members. Amo ng the ag ing popul ation wit h hearing impairme nts, there is a growing demand that thei r hear ing be improved-surgicall y, if possibl e. However, surge ry in the elde rly has var ious degrees of risk , depending on the typ e of procedure. Thi s study was und ertaken to determine what effec t if any that age has on the outco me of hea ling following tympanoplasty.
Materials and methods
Du ring the 5-year period fro m 1986 throu gh 1990 , the author performed 2,4 99 otolog ic proc edures that required ge neral anes thesia. Of thi s total, 599 were min or procedur es (tympanostomy tube placem ent , etc.) and 1,900 were major oto logic procedu res. Of the major procedures, 776 were type I tympanoplastie s. (T his series of type I tympanoplas ties does not includ e proc edures in which the so und-co nducting mechanism was reco nst ruc ted or in which a mastoid ectom y was perform ed .) Th ese type I tymp anopl asties we re perform ed most ofte n on patients younge r than 20 year s and least oft en on patients aged 65 and olde r (table) .
To dete rmine if the patient s in the ge riatric age group ex perienced a disp ro portionate share of heal ing pro blems, their postop erat ive healin g result s were co mpare d with those of patient s aged 20 t040. (T he two groups we re compared only to determ ine the number of proc edures that were req uired to achi eve a we ll-healed tympanic me mbrane. Th e ac tua l postoperati ve hea ring results of the two gro ups were not analyzed.) The postoperati ve followup period ranged fro m 6 to 10 years.
Using the Bellucci cl assific ation ,I the opera ted ear s we re retros pective ly di vided into gro up I (dry perforation with no history of otorrhea) and gro up II (perforatio n with history of inter m itte nt otorr hea, usuall y associated with an upp er res pirato ry infecti on). Surgic al procedures involving ears cat egori zed as gro up III or IV , which usually included a mastoid ectom y and/or oss icular cha in reconstruct ion, we re not stud ied for th is review. A ll procedu res were perfor med by the autho r, who used an und erl ay graft technique as previou sly described .2-5Th e procedures were perform ed eithe r by a tran scanal approach with a perichondrial graft or by a postauricular app roach with a tempora lis fascia graft. Postoperati vely, all patien ts received a IO-day co urse of an anti biotic.
Results
A total of 163 tymp anopl asties were performed in the 20to 40-year-old gro up . Of these, 139 pri mary tymp anopl asties were performed in the Bellucc i gro up I series (including one repea t procedure) and 24 pri mary tympanoplasties were per formed in the Bellucci group II series (includ-ENT·Ear, Nose & Throat Journal" July 1999 Athree-part regimen:
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Discussion
During the preoperati ve co unse ling of old er pati ent s who are con sid ering tympanoplasty, the patient ' s postoperative ex pec tations sho uld be taken into careful con sid eration. In this age gro up, hearing loss is usuall y of the mixed type. Th erefore , the potential for postoper ative hearing gain must be we ighed again st the risk of complications fro m ge neral anesthesia. Because of thi s risk and others , amplificati on is ofte n a more suitable option for the geriatri c patient. Th e most important step in the evaluatio n of the ge riatric pati ent is a care ful preop erat ive assessment of the patient ' s nutritional , cardiovascular, metaboli c, and mental status. Th e preopera tive evaluation by the anes thes iolog ist is perhaps the single most imp ortant part of the ge nera l preoperati ve ass ess me nt. Moreover , the patient' s personal physician should be co nsulted if there are any questi on s conc ern ing the status of the patient' s ge nera l med ical cond ition.
ing three repeat procedur es). All but one ear in the Bellucci gro up I series had a dr y, we ll-healed tymp anic membrane after the initi al operation. A seco nd tympanoplasty was perform ed on this ear, and the tymp anic membrane subsequentl y healed without incid ent. Among the 21 ears that und erwent primar y tymp anopl asty in the Bellu cci group II ser ies, 18 healed initially; the remaining three ears became dry and well healed after a second tympanoplasty.
A total of 97 tympanopl asti es were performed in the o lder gro up. Of these , 88 wer e performed in the Bellucci gro up I seri es, and all ea rs had a dr y, we ll-hea led tymp anic membrane following the initial operatio n. In the Bellucci group II series , six of seven ears healed completely foll owing the initial operatio n. Tw o addition al tympanoplasties were per formed on an ear that did not heal well initiall y.
Fro m the compar ison o f the succes s of graft healin g betw een the youn ger age group and the ge riatric age group, it is evide nt that there was esse ntially no differenc e in the success or failure of the graft-take rate. In addition, other than graft failure, no postoperati ve complications were noted in e ither gro up. Th ere fore , based on this revi ew , it wo uld appear that , in ge neral, age is not a factor in the success or failure in tympanopl asty surge ry.
